Pathalys Pharma

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Upacicalcet(UPASITA)
Phase 3
Calcium-sensing receptor (CaSR)Small molecule
Chronic Kidney Disease
Secondary Hyperparathyroidism

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2032 (1)
February 2032 (1)
Upacicalcet · UPASITAPhase 3Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism
Est. primary completion 2032-02-22 · NCT07890584 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 October 2026Topline resultUpacicalcetPhase 3 PATH-1 and PATH-2 of upacicalcet in hemodialysis patients with secondary hyperparathyroidism met their primary endpoint (J Am Soc Nephrol)
Pathalys Pharma · Source ↗

Financial reports

No financial reports recorded.